Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Epigenetics

Volumn 9, Issue 11, 2014, Pages 1511-1520

  Mithraprabhu, Sridurga ^a   Kalff, Anna ^b   Chow, Annie ^b   Khong, Tiffany ^a   Spencer, Andrew ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Class I HDAC; HDAC expression; Hematological malignancy; Histone deacetylases; Multiple myeloma; Prognosis

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HDAC1 PROTEIN, HUMAN; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PREDICTIVE VALUE; REFERENCE VALUE; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES;

EID: 84922055953     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/15592294.2014.983367     Document Type: Article

References (53)

1. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20; PMID:15809451; http://dx.doi.org/10.1200/ JCO.2005.04.242
2. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-72; PMID:21430775; http://dx.doi.org/ 10.1038/nature09837
3. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12:335-48; PMID:22495321; http://dx.doi.org/ 10.1038/nrc3257
4. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematol Am Soc Hematol Educ Prog 2005:346- 52; PMID:16304402; http://dx.doi.org/10.1182/ asheducation-2005.1.346
5. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23:6333-8; PMID:16155016; http://dx. doi.org/10.1200/JCO.2005.05.021
6. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400; PMID:15765097; http://dx.doi.org/10.1038/ng1531
7. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev 2009; 10:32-42; PMID:19065135; http://dx.doi.org/ 10.1038/nrg2485
8. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277:8-21; PMID:18824292; http://dx.doi.org/ 10.1016/j.canlet.2008.08.016
9. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280:168- 76; PMID:19103471; http://dx.doi.org/10.1016/j. canlet.2008.10.047
10. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007; 72:69- 74; PMID:18004079; http://dx.doi.org/10.1159/ 000111106
11. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Kobel M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (New York, NY) 2008; 10:1021-7; PMID:18714364
12. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9:139-48; PMID:18207460; http://dx.doi.org/10.1016/S1470- 2045(08)70004-4
13. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98:604-10; PMID:18212746; http://dx.doi.org/10.1038/sj. bjc.6604199
14. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14:1669-77; PMID:18347167; http://dx.doi.org/10.1158/1078- 0432.CCR-07-0990
15. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M, Saji S, Suemasu K, Okazaki T, Nakachi K, et al. Prediction of prognosis of estrogen receptor- positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004; 95:496- 502; PMID:15182430; http://dx.doi.org/10.1111/ j.1349-7006.2004.tb03239.x
16. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005; 94:11-6; PMID:16172792; http://dx.doi.org/ 10.1007/s10549-005-6001-1
17. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008; 53:267-77; PMID:18671804; http:// dx.doi.org/10.1111/j.1365-2559.2008.03109.x
18. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 2012; 53:123-9; PMID:21806350; http://dx.doi.org/10.3109/ 10428194.2011.597905
19. Wang JC, Chen C, Dumlao T, Naik S, Chang T, Xiao YY, Sominsky I, Burton J. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008; 49:2321-7; PMID:19052980; http://dx.doi.org/10.1080/10428190802527699
20. Marquard L, Poulsen CB, Gjerdrum LM, de Nully Brown P, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009; 54:688-98; PMID:19438744; http://dx.doi.org/10.1111/j.1365-2559.2009.03290.x
21. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005; 31:376-80; PMID:15837043; http://dx.doi.org/10.1016/j.ejso.2004.11.001
22. Moreno DA, Scrideli CA, Cortez MA, de Paula Queiroz R, Valera ET, da Silva Silveira V, Yunes JA, Brandalise SR, Tone LG. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010; 150:665-73; PMID:20636436; http://dx.doi.org/10.1111/j.1365- 2141.2010.08301.x
23. Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L, Stamatopoulos B. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 2012; 7:1403-12; PMID:23108383; http://dx.doi.org/10.4161/ epi.22674
24. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011; 2011:875824; PMID:21076528; http://dx.doi.org/ 10.1155/2011/875824
25. Ding G, Liu HD, Huang Q, Liang HX, Ding ZH, Liao ZJ, Huang G. HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. FEBS Lett 2013; 587:880-6; PMID:23402884; http://dx.doi.org/10.1016/j.febslet. 2013.02.001
26. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005; 24:4531-9; PMID:15806142; http://dx.doi.org/ 10.1038/sj.onc.1208646
27. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S, Iwase H. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004; 10:6962-8; PMID:15501975; http://dx.doi.org/10.1158/1078- 0432.CCR-04-0455
28. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112:26-32; PMID:15305372; http://dx.doi.org/10.1002/ijc.20395
29. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci 2005; 102:8567-72; PMID:15937109
30. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011; 10:2034-42; PMID:22072815; http://dx.doi.org/10.1158/1535- 7163.MCT-11-0433
31. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119:2579-89; PMID:22262760; http://dx.doi.org/ 10.1182/blood-2011-10-387365
32. Mithraprabhu S, Khong T, Jones SS, Spencer A. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol 2013; PMID:23692150; http://dx.doi.org/10.1111/ bjh.12388
33. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K, Nobuyoshi M, Ozawa K, Kano Y, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010; 116:406-17; PMID:20351311; http://dx.doi.org/10.1182/blood- 2009-07-235663
34. Gazdar AF, Oie HK, Kirsch IR, Hollis GF. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 1986; 67:1542-9; PMID:2423157
35. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991; 78:1996-2004; PMID:1912582
36. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 1993; 53:5320-7; PMID:8221668
37. Kuipers J, Vaandrager JW, Weghuis DO, Pearson PL, Scheres J, Lokhorst HM, Clevers H, Bast BJ. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet 1999; 109:99-107; PMID:10087940; http://dx.doi.org/10.1016/S0165- 4608(98)00157-5
38. Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S, Kwee I, Rinaldi A, Ronchetti D, Verdelli D, et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007; 46:226-38; PMID:17171682; http://dx. doi.org/10.1002/gcc.20404
39. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008:25-31; PMID:18647998; http://dx.doi.org/ 10.1093/jncimonographs/lgn011
40. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000; 97:228-33; PMID:10618400; http://dx. doi.org/10.1073/pnas.97.1.228
41. Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem 2009; 284:30673-83; PMID:19736310; http://dx.doi.org/10.1074/jbc. M109.042242
42. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6:579-89; PMID:22963873; http://dx.doi.org/10.1016/j. molonc.2012.07.003
43. Segre CV, Chiocca S. Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2011; 2011:690848; PMID:21197454; http://dx.doi.org/10.1155/2011/ 690848
44. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26:5420-32; PMID:17694083; http://dx.doi.org/10.1038/sj.onc.1210610
45. Ocio EM, San Miguel JF. The DAC system and associations with multiple myeloma. Invest New Drugs 2010; 28 Suppl 1:S28-35; PMID:21120582; http://dx. doi.org/10.1007/s10637-010-9589-x
46. Clocchiatti A, Florean C, Brancolini C. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. J Cell Mol Med 2011; 15:1833-46; PMID:21435179; http://dx.doi. org/10.1111/j.1582-4934.2011.01321.x
47. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003; 160:1017-27; PMID:12668657; http://dx. doi.org/10.1083/jcb.200209065
48. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008; 19:4062-75; PMID:18632985; http://dx.doi.org/ 10.1091/mbc.E08-02-0139
49. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin E, Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53- independent mechanism. Oncogene 2009; 28:243-56; PMID:18850004; http://dx.doi.org/10.1038/ onc.2008.371
50. Joshi P, Greco TM, Guise AJ, Luo Y, Yu F, Nesvizhskii AI, Cristea IM. The functional interactome landscape of the human histone deacetylase family. Mol Syst Biol 2013; 9:672; PMID:23752268; http://dx.doi.org/ 10.1038/msb.2013.26
51. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10:92-100; PMID:19011628; http://dx.doi.org/10.1038/ni.1673
52. Deubzer HE, Schier MC, Oehme I, Lodrini M, Haendler B, Sommer A, Witt O. HDAC11 is a novel drug target in carcinomas. Int J Cancer 2013; 132:2200-8; PMID:23024001; http://dx.doi.org/10.1002/ijc.27876
53. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45; PMID:11328886; http://dx.doi.org/ 10.1093/nar/29.9.e45